Investment Rating - The report maintains a "Positive" investment rating for the agriculture industry [5] Core Viewpoints - The pig farming sector is expected to benefit from recent policies and market forces that promote capacity reduction, leading to long-term performance improvements [3][36] - The current trend in grain prices is upward, indicating a favorable fundamental outlook for planting and seed industries, highlighting significant investment opportunities [3][36] - The pet food sector is experiencing growth, with increasing recognition of domestic brands and continuous market expansion [3][36] Summary by Relevant Sections Pig Farming - The current pig price is weak, with the average price for external three yuan pigs at 11.82 yuan/kg, a week-on-week increase of 5.82% [10][44] - The industry is entering a phase of capacity reduction, with pig prices expected to stabilize and potentially rise in the long term due to policy support [7][10] Poultry - White feather broiler prices have shown slight increases, with the current price at 6.88 yuan/kg, reflecting a week-on-week rise of 0.15% [13][44] - The yellow feather broiler prices continue to remain strong, indicating a stable market environment [21][44] Feed Sector - Corn prices have decreased slightly, while soybean meal and wheat prices have increased, indicating a mixed market for feed ingredients [23][44] - The average price of pig feed is 3.37 yuan/kg, showing a slight decrease of 0.30% [44] Bulk Agricultural Products - Natural rubber prices have risen, with the current price at 15,335 yuan/ton, a week-on-week increase of 4.36% [30][44] - The report indicates that the down cycle for bulk agricultural products is nearing its end, with signs of recovery in certain segments [30][44]

证券日报网讯 10月24日晚间，瑞普生物发布2025年第三季度报告称，2025年第三季度公司实现营业收 入836，737，374.53元，同比增长1.44%；归属于上市公司股东的净利润为105，784，584.02元，同比 增长23.02%。 （编辑 任世碧） ...

Core Viewpoint - Reap Bio (300119.SZ) reported a strong performance in the first three quarters of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company's operating revenue for the first three quarters reached 2.544 billion yuan, representing a year-on-year increase of 13.50% [1] - The net profit attributable to shareholders of the listed company was 362 million yuan, showing a year-on-year growth of 45.64% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 269 million yuan, reflecting a year-on-year increase of 24.92% [1] - Basic earnings per share stood at 0.7972 yuan [1]

Core Insights - The company reported a revenue of 837 million yuan for Q3 2025, representing a year-on-year increase of 1.44% [1] - The net profit attributable to shareholders was 106 million yuan, showing a year-on-year growth of 23.02% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.54 million yuan, reflecting a year-on-year increase of 7.64% [1]

Core Viewpoint - Reap Bio announced the convening of its 29th temporary board meeting on October 24, 2025, to review the proposal for the Q3 2025 report [1] Company Summary - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio's market capitalization stands at 9.7 billion yuan [1] Industry Summary - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year [1] - There is a contrast in the biopharmaceutical secondary market's activity compared to the primary market, where fundraising has encountered challenges [1]

Core Viewpoint - Reap Bio (300119) reported its Q3 2025 results, showing modest revenue growth and significant profit increase compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved revenue of 837 million, representing a year-on-year growth of 1.44% [1] - The net profit attributable to shareholders for Q3 2025 was 106 million, reflecting a year-on-year increase of 23.02% [1] - For the first three quarters of 2025, the total revenue reached 2.544 billion, with a year-on-year growth of 13.5% [1] - The net profit attributable to shareholders for the first three quarters was 362 million, marking a year-on-year increase of 45.64% [1]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-087 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司《2025年第三季度报告》已于2025年10月25日在深圳 证券交易所网站（http://www.szse.cn）及巨潮资讯网（http://www.cninfo.com.cn） 披露，请投资者注意查阅！ 特此公告。 瑞普生物股份有限公司董事会 二〇二五年十月二十五日 1 瑞普生物股份有限公司 2025年第三季度报告披露提示性公告 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-088 瑞普生物股份有限公司 关于设立及变更募集资金专户并授权签署三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 10 月 24 日召开第五届董事会第二十九次（临时）会议及第五届监事会第二十五次 （临时）会议，审议通过了《关于设立及变更募集资金专户并授权签署三方监管 协议的议案》，同意根据 2021 年向特定对象发行股票部分募集资金投资项目变 更需求，在渤海银行开立新的募集资金专项账户，并变更原在平安银行（账号： 15535008370073）、中国建设银行（账号：12050162660100002432）开立的募集 资金专户用途为"生物制造产业化工程建设项目"。董事会授权董事长及董事长 授权的人员办理开立及变更募集资金专项账户相关事宜，包括但不限于开立募集 资金专项账户、签署募集资金专户存储三方监管协议等。 现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-085 瑞普生物股份有限公司 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过了《关于设立及变更募集资金专户并授权签署三方监管协议的 议案》 第五届监事会第二十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十五次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场表决方式召开。会议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生 主持。本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规 和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，监事会认为公司《2025 年第三季度报告》编制及审议程序符合法 律、行政法规和中国证监会等相关规定，报告内容真实、准确、完整地 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十九次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场结合通讯表决方式召开。会 议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体董事。公司应出 席董事 9 人，实际出席董事 9 人（其中：董事刘爱玲、李睿、杨鶄，独立董事郭 春林、才学鹏、李娅以通讯方式参会），参与表决董事 9 人。本次会议由董事长 李守军先生主持，公司高级管理人员列席了会议。本次会议的召集、召开和表决 程序符合《公司法》《证券法》等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，董事会认为《2025 年第三季度报告》编制和审核的程序符合法律、 行政法规和中国证监会等相关规定，报告内容真实、准确、完整地反映了公司 2025 年三季度的经营状况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事、监事、高级管理人员对该报告签署了书面确认意见。 具体内容详 ...